EUVIMEDEUVIMED entdecken
Crossref

Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

Yingying Luo, Hongwei Jiang, Bimin Shi, Hanqing Cai, Haifang Wang, Shu Li, Wei Qiu, Yunfeng Li, Runze Zhou, Huan Deng, Qun Guo, Li Li und 4 weitere

Contemporary Clinical Trials · 2026

DOI: 10.1016/j.cct.2025.108150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2026. Verfasst von Yingying Luo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Innovent Biologics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Effective weight management and glycemic control are both important in people with type 2 diabetes (T2D) and obesity. Despite the proven benefits of GLP-1 receptor agonists, there is a persistent need for more effective weight management strategies in the treatment of T2D and obesity. Glucagon receptor-based co-agonists, such as mazdutide, represent a promising therapeutic class with the potential for enhanced weight loss compared to current standards of care. However, robust clinical evidence for these agents in populations with T2D and obesity is still lacking. The DREAMS-3 trial is designed to address this gap by directly comparing the efficacy and safety of mazdutide against semaglutide, a widely used GLP-1 receptor agonist, in Chinese adults with T2D and obesity. The results will provide crucial evidence to inform clinical decision-making for this large patient population. METHODS: DREAMS-3 is a randomized, open-label phase 3 trial. Obese Participants (BMI ≥ 28 kg/m2) diagnosed with T2D (≤ 10 years) who had inadequate glycemic control after diet and exercise alone with/without metformin were randomized in a 1:1 ratio to receive mazdutide 6 mg or semaglutide 1 mg once weekly in the 32-week active-controlled treatment period, followed with a 24-week extension period. The primary endpoint is the proportion of participants achieving glycated hemoglobin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesObesityHypoglycemic AgentsHumansMaleFemaleMiddle AgedAdultClinical Trials, Phase III as TopicGlycated HemoglobinWeight LossRandomized Controlled Trials as TopicGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseMetforminPeptidesGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

MazdutideObesitySemaglutideStudy designType 2 diabetes

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlycated HemoglobinGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseMetforminPeptidesGlucagon-Like Peptide 1Semaglutidemazdutide

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
  • Department of Endocrinology, The First Affiliated Hospital and Clinical Medicine College, Henan University of Science and Technology, Luoyang, China.
  • Department of Endocrinology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Endocrinology, The Second Hospital of Jilin University, Changchun, China.
  • Department of Endocrinology, Handan First Hospital, Handan, China.
  • Department of Endocrinology, Huizhou Municipal Central Hospital, Huizhou, China.

Förderung

  • Innovent Biologics

Zitieren

APA

Luo, Y., Jiang, H., Shi, B., Cai, H., Wang, H., Li, S., Qiu, W., Li, Y., Zhou, R., Deng, H., Guo, Q., Li, L., Pei, L., Zhang, H. H., Qian, L., & Ji, L. (2026). Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.108150

Vancouver

Luo Y, Jiang H, Shi B, Cai H, Wang H, Li S, et al. Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemporary Clinical Trials. 2026. doi:10.1016/j.cct.2025.108150

BibTeX
@article{Luo2026,
  author = {Luo, Yingying and Jiang, Hongwei and Shi, Bimin and Cai, Hanqing and Wang, Haifang and Li, Shu and Qiu, Wei and Li, Yunfeng and Zhou, Runze and Deng, Huan and Guo, Qun and Li, Li and Pei, Lijuan and Zhang, Han Han and Qian, Lei and Ji, Linong},
  title = {Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  doi = {10.1016/j.cct.2025.108150}
}
Kostenlos starten →